Can Genetic Testing Improve Mortality Risk?
Genetic testing is now available for many disorders. We have known for centuries that heredity is involved in many diseases. However, 15 years ago the Human Genome project was completed, and the sequence of human DNA is now known. This major accomplishment has caused an explosion of new information about genetic diseases, confirming previous suspicions in many diseases and identifying the genetic contribution in others.
Influenza: The Insurers' Perspective (ALUCA RiskeBusiness)
Seasonal influenza is a unique public health conundrum: its epidemics are annual, yet even with the wealth of epidemiologic data now collected on it, predicting its activity and severity still remains a significant challenge. Recent modeling suggests that the global burden of influenza is worse than previously thought, accounting for up to 600,000 deaths annually.
Milliman IntelliScript Underwriting with Rx Based Models (Slides)
Slides from this presentation, given at the 2018 ACSW Spring Meeting, have been posted at the Actuaries’ Club of the Southwest website.
Mortality Rate Improvements – End of an Era, For Now…
Improvements in mortality rates characterized the twentieth century – the trend of living ever longer and healthier lives seemed assured. Recent mortality rates, however, point to a change. The positive trend has slowed. But why? Are all ages affected? And surely medical advances will anyway have us back on track asap?
Smokeless Fuels the Tobacco Debate
Despite its dwindling popularity in many countries, smoking remains the leading preventable cause of illness and premature death in the world.
Why Wearables are no Gimmick in the Quest for Wellness
It is well understood that increased physical activity levels are linked with a reduced risk of certain illnesses, leading to improved healthy life expectancy. Wearable devices have also been championed as a way to not only help people track physical activity, but with the right incentives, increase overall activity levels in the short term.
Adult Congenital Heart Disease
The definition of congenital heart disease (CHD) is the persistence of any structural abnormality of the heart or great vessels that is present at birth. Those patients with CHD who achieve adulthood are considered to have adult congenital heart disease (ACHD). This is a very heterogenous group, consisting of multiple types of lesions and various stages of repair.
Cancer Mortality Patterns in Insured Lives
For life insurers, a major source of mortality risk mitigation is prudent underwriting at the time of application, which should ultimately reduce future claim costs. One way to refine the underwriting process is through measuring the impact of underwriting using insurance claims experience.
Seasonal Influenza and Mortality
Can big data from a bad flu season yield insights into all-cause mortality and help guide insurance risk assessment? RGA and Blue Dot partner to explore the global spread of infectious disease and arrive at fascinating insights.
Risk Assessment of the Kidney Transplant Recipient
For underwriters, correctly assessing the potential mortality and morbidity risk of applicants who are past renal transplant recipients involves understanding a broad range of issues related to kidney disease, current transplantation science, long term graft success, post-transplant survival predictors, and the common causes of death in kidney transplant recipients.